|Base Year Market Size
|USD 19.2 Billion
|Forecast Year Market Size
|USD 43.1 Billion
|Fastest Growing Market
The global anemia drugs market size was valued at USD 19.2 billion in 2022 and is projected to reach USD 43.1 billion by 2031, registering a CAGR of 9.4% during the forecast period (2023-2031). The region's anemia drugs market growth might be due to increased incidence of the condition, a surge in kidney ailments, and an unhealthy lifestyle.
Anemia pharmaceuticals are pharmacological treatments used to treat anemia, a medical illness defined by a low red blood cell count or hemoglobin concentration in the blood. Various factors, including nutritional deficiencies, chronic diseases, genetic disorders, or drugs can cause anemia. The anemia medicine of choice is determined by the precise cause and degree of the anemia.
The anemia drugs market share is predicted to expand in the next years due to reasons such as an increasing elderly population, a lack of nutritional food among individuals, and an increase in the incidence of chronic diseases such as cancer, diabetes, kidney disease, and others. However, unfavorable effects of anemia prescription medicines are expected to hamper market expansion. On the other hand, growing awareness of anemia in developed and developing nations and research and development related to anemia medications are likely to open up new market prospects.
Anemia's high prevalence is a primary driver of the worldwide anemia medications market. Anemia affects much of the global population, with various underlying factors contributing to its prevalence. Anemia is a global public health problem that affects people of all ages, according to the World Health Organization (WHO), with a prevalence of 24.8% of the world's population. This equates to around 1.62 billion persons suffering from anemia worldwide.
Furthermore, anemia is more common in vulnerable groups such as children, pregnant women, and those living in low- and middle-income nations. According to the WHO, anemia affects approximately 40% of pregnant women worldwide, with greater prevalence in places such as Africa and Southeast Asia. Anemia can also be caused by chronic conditions such as chronic renal disease, cancer, and inflammatory disorders. The increased frequency of chronic diseases, caused by factors such as lifestyle changes and aging populations, contributes to anemia's overall prevalence. Continued attempts to lessen the burden of anemia and improve the well-being of those affected contribute to the anemia drugs market trend.
ESAs, such as erythropoietin, are frequently used to treat anemia, particularly in individuals with chronic renal disease or chemotherapy. However, their use is connected with safety issues, including elevated risks of cardiovascular events and thromboembolic events, as well as potential negative effects on cancer progression. These safety issues may limit its use and create difficulties for patients and healthcare providers. As a result of these safety concerns, regulatory authorities such as the United States Food and Drug Administration (FDA) have imposed restrictions on ESA use. These constraints include requiring more conservative hemoglobin targets, highlighting the significance of a collaborative decision-making process between healthcare practitioners and patients, and publishing black box warnings on ESA labels.
Furthermore, safety concerns about ESAs have considerably impacted clinical practice. Healthcare professionals are now carefully weighing the risks and advantages of ESA medication, particularly in patients with CKD and cancer. They may select other methods or more conservative hemoglobin targets.
Incorporating telemedicine and digital health solutions into the anemia medications market provides chances to improve patient care, increase adherence to treatment regimens, and streamline healthcare delivery for anemia management. Telemedicine allows anemia sufferers to check their vital signs and blood parameters from a distance. Patients, for example, can use portable equipment to regularly assess their hemoglobin levels, blood pressure, and heart rate from the comfort of their homes. This information can be provided to healthcare providers for real-time monitoring and treatment plan updates.
Similarly, digital health technologies may aggregate and analyze patient data, allowing healthcare clinicians to spot trends and make informed treatment decisions. Advanced analytics can assist in identifying high-risk individuals who may require additional monitoring or intervention. According to an American Medical Association poll, the percentage of physicians who believe digital health tools benefit patient care increased from 85% in 2016 to 93% in 2022. As a result, incorporating telemedicine and digital health solutions into anemia management represents an opportunity to change care delivery.
The global anemia drugs market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.
North America is the most significant global Anemia Drugs market shareholder and is estimated to grow at a CAGR of 9.1% over the forecast period. There have been reports of anemia in the United States. As a result, new anemia medications are widely used. The presence of a strong main market player with a robust pipeline aids in regional market growth. In the United States, for example, Global Blood Therapeutics, update 2022, has a strong pipeline of sickle cell disease clinical trials in various stages, such as inclacumab (phase III/IV), GBT021601 (phase I/II), HbF inducers, antisickling agents, inflammation, oxidative stress reduction, and so on.
Furthermore, as the number of infants born in the United States with sickle cell anemia rises, so will the demand for anemia therapy. According to research published in the August 2022 issue of the NCBI by the National Institutes of Health, sickle cell disease (SCD) is a multisystem condition and the most common hereditary disease in the United States, impacting one in every 500 African Americans. In addition, approximately one in every twelve African Americans carries the autosomal recessive mutation, and around 300,000 newborns are born with sickle cell anemia each year. In July 2022, Health Canada accepted for evaluation GSK's daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the potential treatment of chronic kidney disease (CKD) anemia. As a result, new product trials, approvals, and launches provide more efficient medications with diverse applications in anemia, driving the market over the projection period.
Asia-Pacific is anticipated to exhibit a CAGR of 9.9% over the forecast period. The Asia-Pacific region has a significant scope due to developing health infrastructure. The major companies in the Asia-Pacific region are forming new alliances to boost output. According to the National Family Health Survey, India, published in February 2022, the prevalence of anemia was 25.0% in men (15-49 years) and 57.0% in women (15-49 years) in 2021, 31.1% in adolescent boys (15-19 years), 59.1% in adolescent girls, 52.2% in pregnant women (15-49 years), and 67.1% in children (6-59 months). As a result, the survey found a significant burden of anemia, projected to increase demand for anemia therapy and drive market growth over the study period.
Europe is another region with significant development potential. The rising prevalence of iron deficiency in the United Kingdom will drive sales over the projection period. Innovative technology and changing lifestyle habits are predicted to drive demand for aplastic anemia treatment medications in the United Kingdom. Rising per capita income and the presence of several established corporations are driving an increase in the number of R&D activities in this country. The increasing number of new product launches is also expected to boost market growth.
|By Therapy Type
|Amgen GlaxoSmithKline Bluebird Bio Biocon GlycoMimetics Regen Biopharma Bayer Acceleron Pharma Eli Lilly
|U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
|China Korea Japan India Australia Singapore Taiwan South East Asia Rest of Asia-Pacific
|Middle East and Africa
|UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
|Brazil Mexico Argentina Chile Colombia Rest of LATAM
|Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global anemia drugs market is segmented based on type, therapy type, application, and region.
The market is further segmented by type into sickle cell anemia, plastic anemia, and iron-deficiency anemia.
Deficiency anemia holds the major market share. The most frequent type of anemia is iron deficiency anemia. It happens when the body does not have enough iron to form enough healthy red blood cells. Because iron is required for hemoglobin formation, a lack results in decreased oxygen-carrying capacity in the blood. Iron deficiency anemia can be caused by several circumstances, including a lack of iron in the diet, poor iron absorption, blood loss from injury or menstruation, and underlying medical disorders. It is common, affecting people of all ages, and is generally treatable with dietary adjustments or iron supplements.
Sickle cell anemia is a hereditary condition that damages hemoglobin, the oxygen-carrying protein in red blood cells. In sickle cell anemia, hemoglobin molecules assume aberrant, hard forms, causing red blood cells to become malformed and easily broken down. This causes anemia, leading to pain, organ damage, and other consequences.
Based on therapy type, the market is sub-segmented into Oral Iron Therapy, Red Blood Cell Transfusion, and Parental Iron Therapy.
Oral Iron Therapy generates the most income. Oral iron therapy entails taking iron supplements orally in the form of tablets or solutions. It is often used to treat iron deficiency anemia, in which the body does not create enough healthy red blood cells due to a lack of iron. The supplements are designed to replenish iron stores, allowing the bone marrow to create more red blood cells and boost hemoglobin levels.
Transfusion of red blood cells is a medical technique in which a patient gets donated red blood cells intravenously. This therapy is often utilized in cases of severe anemia, major blood loss, or when the body cannot manufacture sufficient healthy red blood cells. Transfusions quickly increase the amount of red blood cells in the recipient's bloodstream, increasing oxygen-carrying capacity.
The segment can be bifurcated by application into Clinic, Healthcare, and Home healthcare.
Healthcare influenced the market growth. A broader range of medical facilities, including hospitals, medical centers, and specialized healthcare institutes, are included in the healthcare application setting. Anemia can be discovered after hospitalizations, surgeries, or while receiving treatment for other medical disorders.
Anemia diagnosis and treatment are often provided in clinical settings such as outpatient clinics or medical offices. Patients see healthcare providers such as primary care physicians or hematologists to be diagnosed with anemia, explore treatment options, and receive recommended drugs or therapy.